|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.50 TWD | +0.71% |
|
-2.13% | +5.52% |
| Market Cap | 11.11B 343M 302M 280M 257M 483M 33.06B 491M 3.33B 1.3B 16.25B 1.29B 1.26B 56.2B | P/E 2024 |
12.6x | P/E 2025 | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 9.67B 299M 263M 244M 224M 421M 28.79B 427M 2.9B 1.13B 14.15B 1.12B 1.1B 48.93B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.29x |
| Free-Float |
44.21% | Yield 2024 |
4.52% | Yield 2025 | 3.4% |
| 1 day | +0.71% | ||
| 1 week | -2.13% | ||
| Current month | -1.82% | ||
| 1 month | -1.51% | ||
| 3 months | +2.05% | ||
| 6 months | +1.39% | ||
| Current year | +5.52% |
| 1 week | 55.7 |  | 58.55 |
| 1 month | 55.7 | | 59 |
| Current year | 53.55 | | 60.55 |
| 1 year | 48.64 | | 60.55 |
| 3 years | 46.55 | | 72.18 |
| 5 years | 33.45 | | 72.36 |
| 10 years | 24.86 | | 72.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tzu Ting Fan
CEO | Chief Executive Officer | - | 2006-05-29 |
Reynold Hsu
DFI | Director of Finance/CFO | - | 2019-07-15 |
Wei Jen Chen
PRN | Corporate Officer/Principal | - | 2001-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Chin Tsai Fan
CHM | Chairman | - | 1967-06-29 |
Yuan Te Li
BRD | Director/Board Member | - | 2012-06-05 |
Tsui Wen Yeh
BRD | Director/Board Member | - | 2002-05-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.71% | -2.13% | +8.84% | -6.26% | 341M | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,057B | |
| +1.59% | +4.09% | +55.34% | +53.96% | 624B | |
| +0.95% | +1.91% | +35.91% | +81.14% | 454B | |
| +1.60% | +6.25% | +33.95% | +29.84% | 341B | |
| -0.60% | +1.52% | +35.68% | +39.76% | 297B | |
| -0.14% | +0.60% | +16.17% | +17.53% | 262B | |
| +0.09% | -2.82% | -28.29% | -41.71% | 215B | |
| +1.22% | +2.66% | +21.87% | +59.73% | 201B | |
| -1.18% | -3.70% | +14.23% | +66.51% | 162B | |
| Average | +0.40% | +0.91% | +24.22% | +46.09% | 361.43B | |
| Weighted average by Cap. | +0.54% | +1.92% | +35.73% | +77.61% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 6.79B 210M 184M 171M 157M 296M 20.21B 300M 2.04B 795M 9.94B 788M 771M 34.35B | 7.02B 217M 191M 177M 163M 306M 20.91B 310M 2.11B 823M 10.28B 815M 797M 35.54B |
| Net income | 881M 27.22M 23.91M 22.23M 20.4M 38.33M 2.62B 38.92M 264M 103M 1.29B 102M 99.97M 4.46B | 928M 28.68M 25.19M 23.42M 21.49M 40.38M 2.76B 41.01M 278M 109M 1.36B 108M 105M 4.69B |
| Net Debt | -1.24B -38.44M -33.76M -31.4M -28.81M -54.14M -3.7B -54.97M -373M -146M -1.82B -144M -141M -6.29B | -1.44B -44.4M -38.99M -36.26M -33.28M -62.52M -4.28B -63.49M -431M -168M -2.1B -167M -163M -7.27B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-24 | NT$56.50 | +0.71% | 294,983 |
| 26-07-23 | NT$56.10 | -2.82% | 992,130 |
| 26-07-22 | NT$57.73 | -0.78% | 921,947 |
| 26-07-21 | NT$58.18 | +0.63% | 429,998 |
| 26-07-20 | NT$57.82 | +0.16% | 372,240 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1720 Stock
Select your edition
All financial news and data tailored to specific country editions
